243 related articles for article (PubMed ID: 12162753)
1. Cost of illness of Crohn's disease.
Bodger K
Pharmacoeconomics; 2002; 20(10):639-52. PubMed ID: 12162753
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
[TBL] [Abstract][Full Text] [Related]
5. Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland.
Holko P; Kawalec P; Mossakowska M; Pilc A
PLoS One; 2016; 11(12):e0168586. PubMed ID: 27992531
[TBL] [Abstract][Full Text] [Related]
6. Economic implications of biological therapies for Crohn's disease: review of infliximab.
Bodger K
Pharmacoeconomics; 2005; 23(9):875-88. PubMed ID: 16153132
[TBL] [Abstract][Full Text] [Related]
7. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.
Bernstein CN; Papineau N; Zajaczkowski J; Rawsthorne P; Okrusko G; Blanchard JF
Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056
[TBL] [Abstract][Full Text] [Related]
8. Advances in the management of Crohn's disease: economic and clinical potential of infliximab.
Hanauer SB; Cohen RD; Becker RV; Larson LR; Vreeland MG
Clin Ther; 1998; 20(5):1009-28. PubMed ID: 9829451
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of infliximab in Crohn's disease.
Smart C; Selinger CP
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
[TBL] [Abstract][Full Text] [Related]
10. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
[TBL] [Abstract][Full Text] [Related]
11. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013.
Bounthavong M; Li M; Watanabe JH
Res Social Adm Pharm; 2017; 13(3):530-538. PubMed ID: 27263802
[TBL] [Abstract][Full Text] [Related]
13. The cost of Crohn's disease: drugs or surgery?
Cohen RD
BioDrugs; 2000 Nov; 14(5):331-44. PubMed ID: 18034577
[TBL] [Abstract][Full Text] [Related]
14. Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective.
Miot J; Smith S; Bhimsan N
Int J Clin Pharm; 2016 Aug; 38(4):880-7. PubMed ID: 27118462
[TBL] [Abstract][Full Text] [Related]
15. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
[TBL] [Abstract][Full Text] [Related]
16. The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.
Floyd DN; Langham S; Séverac HC; Levesque BG
Dig Dis Sci; 2015 Feb; 60(2):299-312. PubMed ID: 25258034
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
18. The cost of illness analysis of inflammatory bowel disease.
Pakdin M; Zarei L; Bagheri Lankarani K; Ghahramani S
BMC Gastroenterol; 2023 Jan; 23(1):21. PubMed ID: 36658489
[TBL] [Abstract][Full Text] [Related]
19. Clinical economics review: medical management of inflammatory bowel disease.
Ward FM; Bodger K; Daly MJ; Heatley RV
Aliment Pharmacol Ther; 1999 Jan; 13(1):15-25. PubMed ID: 9892875
[TBL] [Abstract][Full Text] [Related]
20. Diagnosing Crohn's disease: an economic analysis comparing wireless capsule endoscopy with traditional diagnostic procedures.
Goldfarb NI; Pizzi LT; Fuhr JP; Salvador C; Sikirica V; Kornbluth A; Lewis B
Dis Manag; 2004; 7(4):292-304. PubMed ID: 15671786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
